Nune et al. reports on New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following COVID Vaccinations, mainly Pfizer BioNTech mRNA technology vaccine
Evidence is accumulating (as in this Nune study) that COVID-19 Vaccines ‘May Trigger’ Rheumatic Inflammatory Diseases
https://www.mdpi.com/2076-393X/11/10/1571
‘investigated the demographics, management, and prognosis of new R-IMIDs in adults following SARS-CoV-2 vaccinations.
Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
…A total of 271 cases were reported from 39 countries between January 2021 and May 2023. The mean age of patients was 56 (range 18–90), and most were females (170, 62.5%).
…Most (153, 56.5%) received the Pfizer BioNTech COVID-19 vaccine.
…Nearly 50% of patients developed R-IMID after the second dose of the vaccine.
…Vasculitis was the most prevalent clinical presentation (86, 31.7%), followed by connective tissue disease (66, 24.3%).
…The mean duration between the vaccine’s ‘trigger’ dose and R-IMID was 11 days. Most (220, 81.2%) received corticosteroids; however, 42% (115) received DMARDs such as methotrexate, cyclophosphamide, tocilizumab, anakinra, IV immunoglobulins, plasma exchange, or rituximab.
…Complete remission was achieved in 75 patients (27.7%), and 137 (50.6%) improved following the treatment.
…Two patients died due to myositis.’
Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander
